+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 29Days - 21Years
All Genders
ID05183035

Randomized Trial of Chemotherapy With or Without Venetoclax in Children and Young Adults With Relapsed AML

Led by PedAL BCU, LLC · Updated on 2026-08-24

130

Participants Needed

90

Research Sites

217 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding venetoclax to a chemotherapy treatment using fludarabine, cytarabine, and gemtuzumab ozogamicin can improve survival for children, adolescents, and young adults with acute myeloid leukemia AML who are in first relapse but cannot receive more anthracycline drugs, or those in second relapse. This randomized Phase 3 trial focuses on this patient group with a poor prognosis due to chemotherapy-resistant leukemia cells. Participants receive intensive chemotherapy over two 42-day cycles. In the experimental group, venetoclax is taken orally alongside chemotherapy for the first two cycles, and if clinical benefit is seen but transplant is not possible, maintenance treatment with venetoclax and azacitidine may continue for up to 24 cycles. The control group receives chemotherapy followed by azacitidine alone for maintenance therapy, also up to 24 cycles. Gemtuzumab ozogamicin is given to those whose leukemia cells express CD33. Participants are closely monitored with assessments after the two induction cycles to decide on stem cell transplantation or maintenance therapy. Researchers measure overall survival for up to 5 years, along with response rates, event-free survival, relapse rates, and treatment safety. Blood samples are taken to study venetoclax levels. The total study participation can last several years to track long-term outcomes and adverse events under the care of the study team.

CONDITIONS

Brief Title

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Research Team

G

Gwen Nichols, MD

M

Michel Zwaan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here